Literature DB >> 20378604

Epoxyeicosatrienoates are the dominant eicosanoids in human lungs upon microbial challenge.

L Kiss1, H Schütte, W Padberg, N Weissmann, K Mayer, T Gessler, R Voswinckel, W Seeger, F Grimminger.   

Abstract

Lipoxygenase, cyclo-oxygenase and cytochrome P450 (CYP) products of arachidonic acid (AA) are implicated in pulmonary vasoregulation. The CYP-mediated epoxyeicosatrienoates (EETs) have been described previously as the predominant eicosanoids in human lungs upon stimulation with the Ca(2+) ionophore A23187. In this study, we challenged perfused human lungs with two microbial agents: Escherichia coli haemolysin (ECH) and formyl-methionyl-leucyl-phenylalanine (fMLP). Both stimuli elicited pronounced generation of leukotrienes (LTs), hydroxyeicosatetraenoic acids (HETEs), prostanoids (PTs) and EETs/dihydroxyeicosatrienoic acids (DHETs), as assessed by liquid chromatography-mass spectrometry, paralleled by pulmonary artery pressor response and lung oedema formation. The maximum buffer concentrations of EETs/DHETs surpassed those of LTs plus HETEs and PTs by a factor of four (ECH) or three (AA/fMLP). Dual 5-lipoxygenase/cyclo-oxygenase inhibition caused pronounced reduction of AA/fMLP-induced LT/PT synthesis and oedema formation but only limited attenuation of pulmonary vasoconstriction, while inhibition of CYP epoxygenase clearly attenuated AA/fMLP-induced EET/DHET synthesis and vasoconstriction but not oedema formation, suggesting a major contribution of LTs/PTs to vascular leakage and of EETs/DHETs to pressor response. Consequently, generation of EETs/DHETs is greater than that of LTs plus HETEs and PTs in ex vivo perfused human lungs upon microbial challenge suggesting a substantial contribution of these mediators to inflammatory-infectious pulmonary injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378604     DOI: 10.1183/09031936.00000309

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice.

Authors:  Yong Zhou; Jun Yang; Guo-Ying Sun; Tian Liu; Jia-Xi Duan; Hui-Fang Zhou; Kin Sing Lee; Bruce D Hammock; Xiang Fang; Jian-Xin Jiang; Cha-Xiang Guan
Journal:  Cell Tissue Res       Date:  2015-08-28       Impact factor: 5.249

Review 2.  Omics approaches in cystic fibrosis research: a focus on oxylipin profiling in airway secretions.

Authors:  Jason P Eiserich; Jun Yang; Brian M Morrissey; Bruce D Hammock; Carroll E Cross
Journal:  Ann N Y Acad Sci       Date:  2012-07       Impact factor: 5.691

3.  Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice.

Authors:  Yangmei Deng; Matthew L Edin; Katherine N Theken; Robert N Schuck; Gordon P Flake; M Alison Kannon; Laura M DeGraff; Fred B Lih; Julie Foley; J Alyce Bradbury; Joan P Graves; Kenneth B Tomer; John R Falck; Darryl C Zeldin; Craig R Lee
Journal:  FASEB J       Date:  2010-11-08       Impact factor: 5.191

4.  Blockade or deletion of transient receptor potential vanilloid 4 (TRPV4) is not protective in a murine model of sepsis.

Authors:  Claire A Sand; Anna Starr; Manasi Nandi; Andrew D Grant
Journal:  F1000Res       Date:  2015-04-20

5.  Health benefits attributed to 17α-estradiol, a lifespan-extending compound, are mediated through estrogen receptor α.

Authors:  Shivani N Mann; Niran Hadad; Molly Nelson Holte; Alicia R Rothman; Roshini Sathiaseelan; Samim Ali Mondal; Martin-Paul Agbaga; Archana Unnikrishnan; Malayannan Subramaniam; John Hawse; Derek M Huffman; Willard M Freeman; Michael B Stout
Journal:  Elife       Date:  2020-12-08       Impact factor: 8.140

Review 6.  Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development.

Authors:  Kabir Ahluwalia; Brandon Ebright; Kingsley Chow; Priyal Dave; Andrew Mead; Roy Poblete; Stan G Louie; Isaac Asante
Journal:  Metabolites       Date:  2022-04-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.